Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · IEX Real-Time Price · USD
4.315
-0.155 (-3.47%)
At close: Jul 19, 2024, 4:00 PM
4.310
-0.005 (-0.12%)
Pre-market: Jul 22, 2024, 8:12 AM EDT
Moleculin Biotech Employees
Moleculin Biotech had 18 employees as of December 31, 2023. The number of employees decreased by 1 or -5.26% compared to the previous year.
Employees
18
Change (1Y)
-1
Growth (1Y)
-5.26%
Revenue / Employee
n/a
Profits / Employee
-$1,490,222
Market Cap
9.97M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
PAVmed | 107 |
Tonix Pharmaceuticals Holding | 103 |
Mustang Bio | 80 |
Pieris Pharmaceuticals | 50 |
Plus Therapeutics | 20 |
ABVC BioPharma | 19 |
Traws Pharma | 18 |
Inhibikase Therapeutics | 9 |
MBRX News
- 12 days ago - Moleculin Completes End of Phase 2 Meeting with FDA for Annamycin in AML - PRNewsWire
- 5 weeks ago - Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial - PRNewsWire
- 5 weeks ago - Moleculin to Present at the Virtual Investor Pitch Conference - PRNewsWire
- 6 weeks ago - Moleculin to Participate in the Virtual Investor Lunch Break Series - PRNewsWire
- 2 months ago - Moleculin Abstract Accepted for Poster Presentation at the European Hematology Association (EHA) 2024 Hybrid Congress - PRNewsWire
- 2 months ago - Moleculin Announces Commencement of NIH-Funded Phase 2 Clinical Trial of STAT3 Inhibitor for the Treatment of Glioblastoma (NU 21C06) - PRNewsWire
- 2 months ago - Moleculin Reports First Quarter 2024 Financial Results and Provides Corporate Update - PRNewsWire
- 2 months ago - Moleculin Announces U.S. Patent Issue Notification for Lipid-Based Delivery Technology for Annamycin - PRNewsWire